As Economist Impact’s World Cancer Series continues, Day Two firmly takes up focus on the patient voice, with a presentation by Eileen Page, chief executive of Innovation Advantage 2020 to
Today is set to kick off with a welcome chair of healthcare at Economist Impact, Vivek Muthu, followed by a keynote speech on ‘Cancer control: Global perspectives and European solutions’ by
Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.